Intended for healthcare professionals
Search
Toggle navigation
Current issue
Archive
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
Editorial board
For authors
Advertising
Contact us
News
Web Exclusives
Register
FREE
Sign in
×
Remember me
Not registered?
Forgot your password?
Comment: Mobile phones, the Stewart report and a resurrected neurocutaneous syndrome
Neil Cox
Mobile phones have been extensively in the news over recent months. First there were concerns about brain cancers, followed by major job losses in the mobile phone industry (a sort of proof that what goes up must come down), and most recently the problems of the changes to telephone numbers. I won't elaborate on the latter. Suffice it to say that 25% of phone owners were apparently unaware of the fact that numbers were about to change, and found that their phones were dead.
Dermatology in practice
2001;
9
(4): 4–4
To continue reading this article, please
sign in
or
register
.
Follow us on
|
|
Latest News
EMA committee recommends Galderma’s nemolizumab for prurigo nodularis and atopic dermatitis
LEO Pharma receives MHRA approval for Anzupgo cream in chronic hand eczema
Galderma shares positive phase 3 data for nemolizumab in prurigo nodularis
J&J/Protagonist’s icotrokinra shows promise in phase 3 plaque psoriasis trial
UCB’s Bimzelx approved by FDA to treat hidradenitis suppurativa
This site uses cookies in order to function properly and to allow us to improve our service. By using this site you consent to the use of cookies as set out in our
privacy policy